Dendritic Cell News and Research RSS Feed - Dendritic Cell News and Research

Dendritic Cells are a special type of immune cell that is found in tissues, such as the skin, and boosts immune responses by showing antigens on its surface to other cells of the immune system. A dendritic cell is a type of phagocyte and a type of antigen-presenting cell (APC).
Moffitt Cancer Center initiates phase I clinical trial of cancer vaccine ID-G305

Moffitt Cancer Center initiates phase I clinical trial of cancer vaccine ID-G305

Moffitt Cancer Center has initiated a phase I clinical trial for a new immunotherapy drug, ID-G305, made by Immune Design. Immunotherapy is a treatment option that uses a person's own immune system to fight cancer. It has several advantages over standard cancer therapies, including fewer side effects and an overall better tolerability. It tends to be most effective in patients who have smaller, localized tumors that have not spread to distant sites. [More]
New research may open door to novel therapies for treating immune disorders

New research may open door to novel therapies for treating immune disorders

A new research discovery published in the April 2014 issue of the Journal of Leukocyte Biology may open the door to new therapies that help treat immune disorders or curb runaway inflammation. Specifically, scientists have discovered a molecule that can induce cell death (apoptosis) in a key type of immune cell (dendritic cells). [More]
Shiseido discovers new function of skin immunity that sedates stimuli response of Langerhans cells

Shiseido discovers new function of skin immunity that sedates stimuli response of Langerhans cells

Shiseido Co., Ltd. has long focused its research on skin immunity as an important means of maintaining skin's health, and protecting it from external and internal stressors that can lead to dermatologic problems. [More]

Vaccine-based clinical trial to improve survival outcomes of kidney cancer patients

The Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute has opened a novel Phase III, vaccine-based clinical trial aimed at providing kidney cancer patients long-term control of their disease. [More]
New research may provide insight on how dengue virus gains entry into cells

New research may provide insight on how dengue virus gains entry into cells

Dengue fever, an infectious tropical disease caused by a mosquito-borne virus, afflicts millions of people each year, causing fever, headache, muscle and joint pains and a characteristic skin rash. In some people the disease progresses to a severe, often fatal, form known as dengue hemorrhagic fever. [More]
Incyte enters into clinical trial collaboration agreement with Merck to evaluate safety of IDO1 inhibitor

Incyte enters into clinical trial collaboration agreement with Merck to evaluate safety of IDO1 inhibitor

Incyte Corporation (Nasdaq: INCY) announced today that it has entered into a clinical trial collaboration agreement with Merck, through a Merck subsidiary, to evaluate the safety and efficacy of Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, and Merck's investigational anti-PD-1 immunotherapy, MK-3475, in a Phase I/II study in previously treated metastatic and recurrent non-small cell lung cancer (NSCLC), and other advanced or metastatic cancers. [More]
Clinical trial of experimental vaccine targets cancer stem cells in patients with recurrent brain tumor

Clinical trial of experimental vaccine targets cancer stem cells in patients with recurrent brain tumor

An early-phase clinical trial of an experimental vaccine that targets cancer stem cells in patients with recurrent glioblastoma multiforme, the most common and aggressive malignant brain tumor, has been launched by researchers at Cedars-Sinai's Department of Neurosurgery, Johnnie L. Cochran, Jr. Brain Tumor Center and Department of Neurology. [More]
New approach aims to prevent brain cancer recurrence by attacking tumors at the source

New approach aims to prevent brain cancer recurrence by attacking tumors at the source

Researchers at the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Department of Neurosurgery identified immune system targets on cancer stem cells - cells from which malignant brain tumors are believed to originate and regenerate - and created an experimental vaccine to attack them. [More]

BBC TV report profiles NW Bio's DCVax-L Phase III trial for GBM brain cancer

Northwest Biotherapeutics, Inc.("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that the British Broadcasting Company (BBC) TV network has broadcast a report profiling the first European patient in the Company's Phase III clinical trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM), the most common and aggressive form of brain cancer. [More]
Cellular Biomedicine Group completes TC-DC Phase I clinical trial for hepatocellular carcinoma

Cellular Biomedicine Group completes TC-DC Phase I clinical trial for hepatocellular carcinoma

Cellular Biomedicine Group, Inc., a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, is pleased to announce that it has treated the final patient of its Phase I clinical trial which evaluates the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma, the most common type of liver cancer. [More]

Immunocellular Therapeutics reports positive results from ICT-107 Phase II study in glioblastoma patients

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") announced that ICT-107, its dendritic cell-based vaccine, demonstrated a statistically significant increase in progression-free survival (PFS) in patients with newly diagnosed glioblastoma multiforme (GBM) in its randomized, placebo-controlled phase II trial. [More]
Study: Hospitals vary in management of children with traumatic brain injury

Study: Hospitals vary in management of children with traumatic brain injury

Hospitals vary in management of children with traumatic brain injury—particularly in monitoring and preventing the harmful effects of increased intracranial pressure (ICP), according to a study in the November issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. [More]

SIgN scientist wins prestigious EMBO Young Investigator 2013 award

Dr Florent Ginhoux, Principal Investigator at the Singapore Immunology Network, has been awarded the prestigious EMBO Young Investigator 2013 award. The European Molecular Biology Organization Young Investigator Programme recognises young, promising researchers who are less than forty years of age and who have established their first laboratories in Europe and EMBO cooperation partner countries in the past four years. [More]

Immune Design closes Series C financing totalling up to $49M

Immune Design, a biotechnology company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced it has closed a Series C financing totalling up to $49 million. [More]
Study uncovers new genetic pathways that could revolutionise acute dendritic leukaemia treatment

Study uncovers new genetic pathways that could revolutionise acute dendritic leukaemia treatment

Acute dendritic leukaemia is a rare type of leukaemia, but one with the worst prognosis-the average patient survival rate is just 12-14 months-that is difficult to treat. Juan Cruz Cigudosa's team, from the Spanish National Cancer Research Centre's Molecular Cytogenetics Group, has for the first time sequenced the exome -the coding, or protein-generating, regions of the genome- of dendritic cell leukaemia. [More]
J&J's Janssen Companies Launch A Trio Of Collaborations

J&J's Janssen Companies Launch A Trio Of Collaborations

... [More]
Psoriasis and the nervous system: an interview with Dr Nicole Ward, Case Western Reserve University

Psoriasis and the nervous system: an interview with Dr Nicole Ward, Case Western Reserve University

The prevalence of skin disease exceeds that of obesity, hypertension or cancer. One in three individuals in the United States suffers with a skin disease, with ~2-3% of the American population suffering from psoriasis. [More]
University of Chicago researchers awarded NIH grant to develop novel multiple sclerosis treatment

University of Chicago researchers awarded NIH grant to develop novel multiple sclerosis treatment

Researchers from the University of Chicago have been awarded a five-year, $1.5 million grant from the National Institutes of Health to develop stimulated dendritic cell-derived exosomes that show remarkable promise as a treatment for multiple sclerosis and other neurological diseases involving loss of myelin, the insulation around nerve fibers. [More]
UCSF scientists identify new way to manipulate immune system from autoimmune diseases

UCSF scientists identify new way to manipulate immune system from autoimmune diseases

Scientists from UC San Francisco have identified a new way to manipulate the immune system that may keep it from attacking the body-s own molecules in autoimmune diseases such as type 1 diabetes, rheumatoid arthritis and multiple sclerosis. [More]

New Sponge-Based Therapeutic Cancer Vaccine Begins Human Clinicals

... [More]